Lichen Planus Clinical Trial
Official title:
INCB018424 in the Treatment of Cutaneous Lichen Planus
Verified date | August 2021 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety and efficacy of INCB018424 PHOSPHATE CREAM in cutaneous LP as assessed by the change in Physician Global Assessment (PGA), Body Surface Area (BSA), Index Treatment and Control Lesion by Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (CAILS) score, Pruritus Numerical Rating Scale (NRS), and Skindex-16. To predict responses through the identification of unique biomarkers of LP at week 0 and utilizing RNA sequencing on responsive and non-responsive tissue at week 4.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 25, 2020 |
Est. primary completion date | June 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator. Subjects must give written, signed, and dated informed consent before any study related activity is performed. When appropriate, a legal representative will sign the informed consent according to local laws and regulation Both men and women must be at least 18 years of age at the time of screening Subjects must have clinical and histological features of LP LP must involve between 2 and 20% of the BSA Subjects must have a minimum of 10 lesions of LP Subjects must have treatment naive cutaneous LP or treatment refractory disease, as defined by failure of at least one established treatment for LP Failure of prior therapy Topical treatment Systemic immunosuppressant Oral metronidazole Oral sulfasalazine Oral retinoid |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Aaron R. Mangold |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) | mCAILS summation score as measured by Erythema (0-8), Scaling (0-8) Plaque elevation (0-8) Hyper/hypopigmentation (0-8) Size (0-18), Total score ranging from 0-50 with higher score indicating higher severity | week 0, week 4 | |
Primary | Change in Total Body Lesion Count | The number of total body lesions. | week 0, week 4 | |
Secondary | Change in Pruritus Numerical Rating Scale | Pruritus Numerical Rating Scale as measured by they question "How severe has your itching been over the last 24 hours?" Ranging from 0 = none, to 10 = severe. The higher the score the more severe. | week 0, week 4 | |
Secondary | Change in Overall Quality of Life Skindex-16 Score | Skindex-16 score as measured by 16 questions, 3 subscales: Symptoms, Emotional, Functional. Score ranges for each question (0-6). Total score ranging from 0-96 with higher score indicating worse quality of life | week 0, week 4 | |
Secondary | Number of Subjects With Greater Than or Equal to 50% Improvement in Physician Global Assessment Score | PGA score as measured by Grade 0 (clear: no evidence of disease (100% improvement)) to Grade 6 (Worse, disease is worse than at baseline evaluation by (=25%) or more). Higher score equals worse disease | week 0, week 4 | |
Secondary | Body Surface Area (BSA) Affected by Cutaneous Lichen Planus | BSA as measured as the percentage of the body affected by Cutaneous Lichen Planus. Ranging from 0-100% of the body. | week 0, week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06021405 -
Koebner's Phenomenon in Psoriasis and Lichen Planus
|
N/A | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT05787925 -
Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus
|
N/A | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Completed |
NCT04952961 -
Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study
|
N/A | |
Recruiting |
NCT04697563 -
Laser Therapy in Women With Lichenoid Disorders
|
N/A | |
Completed |
NCT03265093 -
Use of Injectable Platelet Rich Fibrin in Lichen Planus
|
N/A | |
Completed |
NCT03858634 -
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
|
Phase 2 | |
Completed |
NCT02761122 -
Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)
|
N/A | |
Active, not recruiting |
NCT00691106 -
A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus
|
Phase 2 | |
Terminated |
NCT05761158 -
Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
|
||
Recruiting |
NCT02261662 -
Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
|
N/A | |
Not yet recruiting |
NCT04892381 -
Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
|
||
Completed |
NCT05396261 -
a Flexible Wound Dressing for the Management of Genital Skin Conditions
|
N/A | |
Recruiting |
NCT02532166 -
Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus
|
N/A | |
Recruiting |
NCT06327620 -
Treatment Of Oral Lichen Planus
|
N/A | |
Completed |
NCT03796806 -
Methods Validation Assessment for Study of Inflammatory Skin Disease
|
||
Completed |
NCT02850601 -
Dexamethasone Solution for the Treatment of Oral Lichen Planus
|
Phase 2 | |
Not yet recruiting |
NCT01041625 -
Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus
|
Phase 2 | |
Completed |
NCT00824889 -
Exploratory Study of Natural Killer Cells in Human Skin
|
N/A |